In their analysis, insulins and TZDs were associated with weight gain of 1.85–5.00 kg, GLP-1 analogues were associated with modest weight loss, and DPP-4 inhibitor was weight-neutral and did not show any increase in hypoglycaemia which was found when insulin was used. This evidence concerns the gene GCG and Hypoglycemia.